Hiltonol
- Generic Name
- Hiltonol
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 59789-29-6
- Unique Ingredient Identifier
- 7KYP9TKT70
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies
- Conditions
- Interventions
- First Posted Date
- 2016-03-28
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Nina Bhardwaj
- Target Recruit Count
- 13
- Registration Number
- NCT02721043
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2022-12-02
- Lead Sponsor
- Ludwig Institute for Cancer Research
- Target Recruit Count
- 58
- Registration Number
- NCT02643303
- Locations
- 🇺🇸
Research Facility, Charlottesville, Virginia, United States
Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2015-07-29
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 1
- Registration Number
- NCT02510950
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT02427581
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- Conditions
- Interventions
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 56
- Registration Number
- NCT02287428
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT02166905
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 60
- Registration Number
- NCT02129075
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 3
- Registration Number
- NCT02061449
- Locations
- 🇺🇸
NYU Cancer Institute, New York, New York, United States
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- Nina Bhardwaj
- Target Recruit Count
- 8
- Registration Number
- NCT01984892
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
- Conditions
- Interventions
- First Posted Date
- 2013-11-06
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Joshua Brody
- Target Recruit Count
- 21
- Registration Number
- NCT01976585
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.